NeoRx receives delisting warning from Nasdaq

New York, Jan. 11 - NeoRx Corp. said it received a notice from the Nasdaq Stock Market, Inc. warned that it is in danger of being delisted because the minimum bid price of its stock has fallen below $1.00 for 30 consecutive business days.

The Seattle-based specialty pharmaceutical company has 180 days - until July 10 - to regain compliance by having its stock close above $1.00 per share for at least 10 consecutive business days.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.